Genenta Science (ADR) (GNTA)
Develops tumor-targeted gene therapy and staged Italian defense and aerospace investments.
Something off on this page? Send us feedback.
Develops Temferon, an investigational tumor-targeted gene therapy, while pursuing staged control investments in Italian defense and aerospace businesses. The model combines externally supported clinical development with a planned portfolio of regulated industrial operators.
Develops Temferon, an autologous stem/progenitor-cell gene therapy designed to direct interferon-alpha into solid-tumor microenvironments through its myeloid-cell progeny. The investigational program completed a glioblastoma study and continues clinical work in genitourinary tumors, using research and clinical relationships in Milan while collaboration options remain under review.
Is moving from a clinical-stage biotechnology focus toward staged investments in Italian national-security-regulated businesses. A.T.C. makes high-precision tactical rifles and weapon systems; Sòphia High Tech provides aerospace-and-defense engineering and manufacturing. Both investments are structured to progress from minority ownership to control under operating, licensing, contractual and regulatory conditions. Temferon has no approved product, sales or distribution infrastructure, and the corporate-purpose expansion remains suspended.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Dec 31, 2025Cash & short-term investments $32.1M · Total debt $8.7M · Total assets $36.4M · Shareholders' equity $24.9M
- Revenue
- $0
- Operating income
- −$3.6M
- Net income
- −$3.1M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 3.76% | 720.7K ADS | |
|---|---|---|---|
| 9 holders · as of Jun 30, 2026 | |||
| Insiders | 22.22% | 4.25M ADS | |
| 4 holders · as of Mar 18, 2026 | |||
| Other | 74.02% | 14.17M ADS | |
| remainder | |||
19.15M ADS as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Paracchi PierluigiInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 12.03% | 2.28M ordinary · 27,000 ADS | filed Mar 18, 2026 |
San RaffaeleInsider | 9.91% | 1.90M | filed Feb 25, 2022 |
Eurizon Capital SGR S.P.A.Institution | 1.88% | 360,000 ADS | as of Jun 30, 2026 |
Allianz SEInstitution | 1.22% | 234,050 ADS | as of Jun 30, 2026 |
Smartharvest Portfolios, LLCInstitution | 0.23% | 43,856 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Candel Therapeutics
Oncolytic immunotherapy rival in glioblastoma.
- Novocure
Established glioblastoma therapy competing for the same patients.
- Merck
Checkpoint-inhibitor regimens dominate the renal-cell pathway.
- Bristol-Myers Squibb
Opdivo-based combinations are leading RCC treatment options.
- ImmunityBio
Cytokine and NK-cell immunotherapy challenger across solid tumors.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genenta Science (ADR) | $0.7113 | +1.04% | $13.5M | — | — | — | — |
| Candel Therapeutics | $11.81 | −0.34% | $868.3M | — | — | — | — |
| Novocure | $16.47 | −1.23% | $1.94B | — | — | 2.8 | +15.6% |
| Merck | $149.80 | −0.74% | $372.73B | 120.7 | 17.4 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $61.87 | −0.61% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| ImmunityBio | $8.84 | −4.84% | $9.73B | — | — | 58.7 | +93.9% |
| Median | 67.2 | 13.5 | 4.2 | +10.7% |